Salute e Benessere

Press Release: Availability of the Q1 2025 Aide mémoire

Availability of the Q1 2025 Aide mémoireParis, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count...
Nasdaq GlobeNewswire
24/03/2025

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ®…

Saint Herblain (France), March 24, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France's Island of La Réunion with its vaccine IXCHIQ ®. In agreement and with support from the local public health agency, theAgence Régionale de SantéLa Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution...
Nasdaq GlobeNewswire
24/03/2025

Santhera to share latest on commercial rollout of AGAMREE® and future strategic…

Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy (DMD). The Company will also outline plans for further market expansion and provide an update on its strategic direction beyond DMD. The Company continues to evaluate opportunities to expand its rare disease portfolio as...
Nasdaq GlobeNewswire
24/03/2025

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination…

Globally, liver cancer is a common malignant tumor of the digestive system, and the main pathological type is HCC (accounting for about 90%). According to data released by the GLOBOCAN for 2022, the annual number of new cases and deaths of liver cancer worldwide was 866,000 and 759,000, respectively. China has a high incidence of liver cancer. In 2022, the number of new liver cancer cases reached 368,000 (accounting for 42.4% of global cases), ranking fourth among domestic malignant tumors,...
Nasdaq GlobeNewswire
24/03/2025

AWE 2025: MOVA Sparks New Wave in Smart Home Technology with Ultimate Innovation

At the event, MOVA, with its innovative, high-end, and fashionable positioning, became the undeniable focal point of the exhibition and won accolades such as the AWE Innovation Award from the AWE organizer. At the event, MOVA, with its innovative, high-end, and fashionable positioning, became the undeniable focal point of the exhibition and won accolades such as the AWE Innovation Award from the AWE organizer. Throughout the exhibition, it was graced by celebrities, with notable figures like...
PR Newswire
23/03/2025

Financière de Tubize - Annual report 2024

Annual Report 2024 Regulated information 22 March 2025The board of directors of Financière de Tubize has established the 2024 annual report. This report is available on the website www.financiere-tubize.be Profit for the financial year: € 90.1 million (€ 88.2 million in 2023, + 2,2%),Reduction of outstanding bank borrowings from € 79.2 million at 31 December 2023 to € 41.3 million at 31 December 2024,Acquisition, in 2024, of 53,706 UCB shares, increasing the holding of the Company in...
Nasdaq GlobeNewswire
22/03/2025

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by…

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously defend the companyCOPENHAGEN, Denmark; March 22, 2025 –Genmab A/S(Nasdaq: GMAB) announced today that AbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle)naming Genmab A/S; ProfoundBio US Co.; ProfoundBio...
Nasdaq GlobeNewswire
22/03/2025

Cardiac Biomarkers Market to be Worth $10.08 Billion by 2031--Exclusive Report…

The cardiac biomarkers market is primarily driven by several factors, including the increasing prevalence of cardiovascular diseases, technological advancements in biomarker testing, rising geriatric population leading to a higher incidence of heart-related conditions, increasing healthcare expenditure, and growing awareness programs on cardiovascular diseases. The cardiac biomarkers market is primarily driven by several factors, including the increasing prevalence of cardiovascular diseases,...
PR Newswire
21/03/2025

US Healthcare Analytics Market worth US$47.40 billion by 2029 with 24.5% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=905 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=905 Browse in-depth TOC on "US Healthcare Analytics Market" 150 - Tables50 - Figures Based on type, the descriptive analytics segment is projected to account for the largest share of US healthcare analytics market in 2023. The rising need for data-driven decision-making based on historical trends is a key...
PR Newswire
21/03/2025

Hansa Biopharma publishes 2024 Annual and Sustainability Reports

Søren Tulstrup, President and CEO, Hansa Biopharma, said, "2024 was a momentum-building year for Hansa. With year-on-year IDEFIRIX® sales growth of 83%, a successful financing round, and several critical pipeline catalysts for imlifidase and HNSA-5487, 2024 has positioned us well to advance our efforts in Autoimmune, Gene Therapy and Transplantation. 2025 promises to be an exciting and important year, marked by several data readouts and a planned BLA submission to the U.S. FDA in kidney…
PR Newswire
21/03/2025

Hospital Information Systems Market worth US$116.75 billion by 2030 with 10.6%…

Browse in-depth TOC on "Hospital Information Systems Market" Browse in-depth TOC on "Hospital Information Systems Market" 400 - Tables50 - Figures400 - Pages By Based on product type,the Electronic Health Record (EHR) segment is estimated to hold the second-largest share of the hospital information systems market. Key growth drivers include strong federal mandates like the American Recovery and Reinvestment Act of 2009 (ARRA), which have spurred comprehensive EHR...
PR Newswire
21/03/2025

Task Trainers Market to Reach $2.9 Billion by 2032--Exclusive Report by…

Download FREE PDF Brochure of Task Trainers Market – https://www.meticulousresearch.com/download-sample-report/cp_id=2412 Download FREE PDF Brochure of Task Trainers Market –https://www.meticulousresearch.com/download-sample-report/cp_id=2412 The task trainers market is segmented by product, by application, and by end user. The study also evaluates industry competitors and analyzes the market at the global and regional levels. Task Trainers Market Analysis: Key Findings Based...
PR Newswire
21/03/2025

Bioretec Ltd's Board of Directors has decided on a new option program for the…

There is a weighty financial reason for issuing option rights, as the option program is part of the incentive and commitment program of the CEO. There is a weighty financial reason for issuing option rights, as the option program is part of the incentive and commitment program of the CEO. The Board of Directors has resolved to issue 610,105 option rights to the CEO. Each of the option rights entitle to the subscription of one (1) share in the company. The option rights are issued free of...
PR Newswire
21/03/2025

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive…

The Annual General Meeting approved the financial statements for the financial year 1 January-31 December 2024 and resolved to discharge the members of the Board of Directors and the CEO from liability for the financial period 1 January-31 December 2024. The Annual General Meeting approved the financial statements for the financial year 1 January- 31 December 2024and resolved to discharge the members of the Board of Directors and the CEO from liability for the financial period 1 January- 31...
PR Newswire
21/03/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 21 March 2025 at 15.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 20 March 2025...
Nasdaq GlobeNewswire
21/03/2025

Pharmaceutical industry delivers value proposition to Finnish Government…

ORION CORPORATIONPRESS RELEASE21 MARCH 2025 at 13:00 EETPharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 In 2023, pharmaceutical companies invested more than EUR 460 million in Finland, half of which went into R&D and the other half into production.On Friday 21 March, representatives of the pharmaceutical industry submitted the sector's value proposition to Riikka Purra, the Minister of Finance. The industry wants to play...
Nasdaq GlobeNewswire
21/03/2025

CARBIOS announces changes to its governance and reaffirms its strategic…

The Board of Directors has appointed Isabelle PARIZE as its Chairwoman and Vincent KAMEL as Chief Executive Officer with immediate effect CARBIOS reaffirms its objective of building its PET biorecycling plant in Longlaville once additional financing has been secured Clermont-Ferrand (France), Friday 21 March 2025 (8:00am CET). CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of...
Nasdaq GlobeNewswire
21/03/2025

Recognising Excellence in Medicine: The 50 Best Doctors in the UK for 2024…

Thousands of medical professionals voted to identify the most outstanding doctors based on expertise, patient care, and contributions to their field.More than 5,000 votes were cast, evaluating specialists on reputation, clinical skills, research, teaching, and medical outreach. Doctors also nominated peers they would recommend to their own family or friends. "These awards highlight professionalism, medical excellence, and dedication. At Top Doctors Group, we are committed to...
PR Newswire
21/03/2025

Driven by its Pharmaceutical Activities, Roquette's 2024 Results Demonstrate the…

Driven by its Pharmaceutical Activities, Roquette's 2024 Results Demonstrate the Resilience of its Integrated Business Model Commercial performance in line with a market which remains below historical levels. 2024 turnover of €4,495 million (-10% vs. 2023).Rigorous cost management has allowed the Group to maintain margin levels (11.8% in 2024 compared with 12.2% in 2023), with a consolidated EBITDA of €529 million (-13% vs. 2023).A significant improvement in Free Cash-Flow, at...
Nasdaq GlobeNewswire
21/03/2025

UCB Convening Notice to the General Meeting of the Shareholders 2025

CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the ordinary general meeting of the shareholders (the “ General Meeting ”) which will be held onThursday, 24 April 2025, at 11:00 am CEST,at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at the end of this...
Nasdaq GlobeNewswire
21/03/2025

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…

Novartis receives third FDA approval for oral Fabhalta ®(iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one year with favorable safety 1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G 1-3 C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure 2-4 ...
Nasdaq GlobeNewswire
21/03/2025

Oculis Publishes Notifications of Transactions by Person Discharging Managerial…

Attachments PDMR notification - R. Sherif - sales 14 Mar 2025PDMR notification - R. Sherif - sales 17 Mar 2025PDMR notification - R. Sherif - sales 18 Mar 2025PDMR notification - R. Sherif - sales 19 Mar 2025PDMR notification - R. Sherif - sales 20 Mar 2025
Nasdaq GlobeNewswire
20/03/2025

Regulatory Analysis: Unlocking Dermatology Success - Strategic Insights for…

To navigate this complex regulatory analysis landscape, the client partnered with DelveInsight, leveraging their expertise to gain a comprehensive and actionable understanding of CDSCO's latest review protocols and approval mechanisms for pharmaceutical products. To navigate this complex regulatory analysis landscape , the client partnered withDelveInsight, leveraging their expertise to gain a comprehensive and actionable understanding of CDSCO's latest review protocols and approval...
PR Newswire
20/03/2025

DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market…

Janssen's DARZALEX (daratumumab, JNJ-54767414) Overview Janssen's DARZALEX (daratumumab, JNJ-54767414) Overview DARZALEX (daratumumab) is a prescription medication used to treat multiple myeloma, a type of blood cancer. It is not a chemotherapy drug but a human IgG1k monoclonal antibody that binds strongly to the CD38 molecule, which is highly expressed in multiple myeloma cells. Daratumumab works by activating the immune system to target and destroy cancer cells, leading to rapid tumor...
PR Newswire
20/03/2025
Altri  Comunicati